Current Perspectives of Immunotherapy for Hepatocellular Carcinoma

Title:Current Perspectives of Immunotherapy for Hepatocellular Carcinoma

Volume: 27

Author(s): Xiaoyi Liu, Xiaoyong Lei, Sheng Huang and Xiaoyan Yang*

Affiliation:

• School of Pharmaceutical Science, Hengyang Medical College, University of South China, 28 Western Changsheng Road, Hengyang, Hunan 421001, People's Republic of China
• Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, University of South China, 28 Western Changsheng Road, Hengyang, Hunan 421001, People's Republic of China

Abstract: Hepatocellular carcinoma is the sixth most common tumor and the third leading cause of cancer death worldwide. It ranks fourth in the spectrum of malignant tumor incidence and second in the order of death from major malignant tumors in China. Hepatocellular carcinoma is a complex ecosystem containing non-tumor cells (mainly immune-related cells), and its immunotherapy can stimulate the recognition of specific tumor antigens, inhibit the proliferation of cancer cells, and produce over-memory lymphocytes, which can prevent recurrence. So, immunotherapy of hepatocellular carcinoma is increasingly becoming a research hotspot in liver cancer treatment. With the intensive research in recent years, great progress has been made in immunotherapy for hepatocellular carcinoma, including immune checkpoint inhibitors, pericyte therapy, vaccination, and antiviral therapy. In addition, the study found that the therapeutic effect of combination therapy was enhanced compared to monotherapy. This review summarizes the most prominent immunotherapies currently available for the clinical treatment of patients with HCC and the main opportunities and challenges facing HCC research.

Cite this article as:

Liu Xiaoyi, Lei Xiaoyong, Huang Sheng and Yang Xiaoyan*, Current Perspectives of Immunotherapy for Hepatocellular Carcinoma, Combinatorial Chemistry & High Throughput Screening 2024; 27 () . https://dx.doi.org/10.2174/0113862073255266231025111125